Unlike traditional treatments that target only CSF production, GLP-1 agonists may work through two pathways: Weight loss - a major long-term treatment for IIH Possible CSF pressure effects - GLP-1 receptors on the choroid plexus (where CSF is made) may reduce fluid secretion independent of weight loss The IIH Pressure Trial ( Brain , 2023) found that exenatide lowered intracranial pressure within hours of the first dose
Low-impact exercises, such as swimming, cycling, or yoga, are generally recommended to maintain joint function while minimizing strain
Doctors use semaglutide, a man-made GLP-1 receptor agonist, to manage type 2 diabetes
GLP-1 (Glucagon-like Peptide-1) is a hormone produced in the small intestine that helps regulate blood sugar levels by: Enhancing insulin secretion Suppressing glucagon release Slowing gastric emptying Reducing appetite What makes GLP-1 agonists especially promising is their broad distribution of receptors throughout the body, including in the brain, heart, kidneys, lungs, skin, and gastrointestinal tractindicating potential systemic effects that go well beyond glucose control
Several clinical trials have demonstrated that commonly used SGLT2i, including canagliflozin, dapagliflozin, and empagliflozin, can slow down kidney disease progression and reduce morbidity and mortality in patients with CKD, regardless of the presence of diabetes mellitus [155,156,157,158]
